Anthony Joshua
St Vinents Hospital sydney · St Vincent's Hospital, Sydney · University Health Network, Toronto
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony Joshua as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:23 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07203391 · Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney · recruiting · Uveal Melanoma, Metastatic · principal investigator
- Ph1/Ph2NCT07063875 · Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionSt Vincent's Hospital, Sydney · recruiting · Uveal Melanoma, Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver · principal investigator
- Ph2NCT06594926 · Working Out M0 Bipolar Androgen TherapyAustralian and New Zealand Urogenital and Prostate Cancer Trials Group · recruiting · Prostate Cancer · study chair
- Ph2NCT05187884 · Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaSt Vincent's Hospital, Sydney · completed · Ocular Melanoma · principal investigator
- Ph1NCT05156892 · Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian CancerAnthony Joshua, FRACP · active not recruiting · Ovarian Cancer · principal investigator
- Ph1/Ph2NCT03513211 · Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate CancerSt Vincent's Hospital, Sydney · completed · Prostate Cancer · principal investigator
- Ph2NCT02543255 · Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)University Health Network, Toronto · completed · Prostate Cancer · principal investigator
- Ph2NCT02429193 · Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSAUniversity Health Network, Toronto · completed · Castration-resistant Prostate Cancer · principal investigator
- N/ANCT02251314 · Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant MelanomaUniversity Health Network, Toronto · completed · Melanoma · principal investigator
- Ph3NCT01864096 · The Metformin Active Surveillance Trial (MAST) StudyUniversity Health Network, Toronto · unknown · Prostate Cancer · principal investigator
- N/ANCT01857908 · A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With AbirateroneUniversity Health Network, Toronto · completed · Prostate Cancer (Adenocarcinoma) · principal investigator
- N/ANCT01715077 · Study of Ipilimumab in the Immune SystemUniversity Health Network, Toronto · completed · Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma · principal investigator
- Ph2NCT00881725 · A Study of Pre-operative Metformin in Prostate CancerUniversity Health Network, Toronto · terminated · Prostate Cancer · principal investigator
- Ph2NCT00480090 · A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate CancerUniversity Health Network, Toronto · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:23 UTC. The ranking covers the 200 most relevant of 82 PubMed records, and a shared surname and initials can bring in a namesake. All 82 on PubMed
- Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.N Engl J Med · 20132,803 citationsRCR 76.7
- Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med · 20142,392 citationsRCR 70.7
- 1,500 citationsRCR 40.5
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.N Engl J Med · 20191,331 citationsRCR 51.5
- 966 citationsRCR 59.1
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.JAMA · 2016879 citationsRCR 25.8
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.Ann Oncol · 2019771 citationsRCR 27.0
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.J Clin Oncol · 2016614 citationsRCR 18.5
- Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.J Clin Oncol · 2016559 citationsRCR 17.0